Aurobindo Pharma receives final approval for Venlafaxine Hydrochloride Tablets

8th April 2010

Aurobindo Pharma Limited is pleased to announce that it has received the final approval for Venlafaxine Hydrochloride Tablets 25mg, 37.5mg, 50mg, 75mg and 100mg from the US Food & Drug Administration (USFDA).

Venlafaxine Hydrochloride Tablets 25mg, 37.5mg, 50mg, 75mg and 100mg are the generic equivalent of Wythe Pharmaceutical's Effexor® Tablets 25mg, 37.5mg, 50mg, 75mg and 100mg.

Venlafaxine Hydrochloride Tablets are indicated for the treatment of major depressive disorder (MDD) and falls under the therapeutic category of CNS (Central Nervous System). The product will be launched shortly.

Aurobindo has a total of 114 ANDA approvals (85 Final approvals and 29 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com